Teza Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Teza Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,026	Closed	-$602K	–	571
2024 Q1	$602K	Sell	4,026 -7,396	-65%	-$1.23M	0.08%	309
2023 Q4	$2.19M	Buy	+11,422	New	+$1.95M	0.37%	71
2023 Q2	–	Sell	-1,735	Closed	-$348K	–	559
2023 Q1	$348K	Buy	+1,735	New	+$365K	0.08%	352
2020 Q3	–	Sell	-7,437	Closed	-$1.1M	–	362
2020 Q2	$1.1M	Buy	7,437 +5,433	+271%	+$732K	0.24%	123
2020 Q1	$218K	Sell	2,004 -717	-26%	-$82.8K	0.7%	66
2019 Q4	$313K	Buy	+2,721	New	+$271K	0.09%	412

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Teza Capital Management's ALNY Position: Q2 2024 in Review

Teza Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 4,026 shares — an estimated $602K sold.

Teza Capital Management first reported a position in ALNY in Q4 2019 and held it in 6 quarters. The position peaked at $2.19M in Q4 2023. 523 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

Teza Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Teza Capital Management sold 4,026 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $602K.
Teza Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 6 quarters.
Teza Capital Management's Alnylam Pharmaceuticals position peaked at $2.19M in Q4 2023.
523 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Teza Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.